20
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Tolerance of Efavirenz-Induced Central Nervous System Side Effects in HIV-Infected Individuals with a History of Substance Abuse

, &
Pages 145-149 | Published online: 14 Jan 2015

REFERENCES

  • Centers for Disease Control and Prevention. Drug-associ-ated HIV transmission continues in the United States. May 2002. www.cdc.gov/hiv/pubs/facts/idu.htm Accessed De-cember 6, 2002.
  • Turner BJ, Fleishman JA, Wenger N, et al. Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med. 200116: 625–633.
  • Lucas GM, Gebo K, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16:767–774.
  • Mocroft A, Madge S, Johnson A, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy, response to HAART, and sur-vival. J Acquire Immune Defic Syndr. 1999;22:369–378.
  • Palepu A, Yip B, Miller C, et al. Factors associated with the response to antiretroviral therapy among HIV-infected pa-tients with and without a history of injection drug use. AIDS. 200115: 423–424.
  • Hirschel B, Flepp M, Bucher H, et al. Switching from pro-tease inhibitors to efavirenz: differences in efficacy and tolerability among risk groups: a case control study from the Swiss HIV cohort. AIDS. 2002;16:381–385.
  • Bristol-Myers Squibb Company. Sustiva product informa-tion. Princeton, NJ: Bristol-Myers Squibb Company; 2002.
  • Marzolini C, Troillet N, Telenti A, et al. Efavirenz decreases methadone blood concentrations. AIDS. 2000;14:1291–1292.
  • Boffito M, Rossati A, Reynolds H, et al. Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment. AIDS Res Hum Retroviruses. 2002;18:341–342.
  • Clarke SM, Mulcahy FM. Efavirenz therapy in drug users. HIV Med. 2000;1(S1):15–17.
  • Guest JL, DeSilva KE, Flaherty TD, et al. Tolerability of efavirenz in patients with a history of mental health disorder or substance abuse: data from HAVACS. In: Program and abstracts of the XIV International AIDS Conference; July 7–12, 2002; Barcelona, Spain. Abstract TuPeB4502.
  • Ferrando SJ, Wall TL, Batki SL, Sorenson JL. Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. Am J Drug Alcohol Abuse. 1996;22:475–487.
  • National Institute on Drug Abuse. Research Report Se-ries-Heroin Abuse and Addiction. Last updated October 21, 2002. http://www.nida.nih.gov/ResearchReports/Heroin/heroin3.html#short Accessed December 6, 2002.
  • National Institute on Drug Abuse. Research Report Series - Cocaine Abuse and Addiction. Last updated November 25, 2002. http://165.112.78.61/ResearchReports/Cocaine/cocaine3.html Accessed December 6, 2002.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.